Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.45 Billion INR | -0.64% |
| 2022 | 13.53 Billion INR | 0.14% |
| 2021 | 13.52 Billion INR | -1.07% |
| 2020 | 13.66 Billion INR | 3.95% |
| 2019 | 13.14 Billion INR | 3.14% |
| 2018 | 12.74 Billion INR | -1.35% |
| 2017 | 12.92 Billion INR | 0.94% |
| 2016 | 12.8 Billion INR | -1.55% |
| 2015 | 13 Billion INR | 2.6% |
| 2014 | 12.67 Billion INR | -1.1% |
| 2013 | 12.81 Billion INR | 7.68% |
| 2012 | 11.9 Billion INR | -4.57% |
| 2011 | 12.47 Billion INR | 37.44% |
| 2010 | 9.07 Billion INR | 21.59% |
| 2009 | 7.46 Billion INR | 30.4% |
| 2008 | 5.72 Billion INR | 6.16% |
| 2007 | 5.39 Billion INR | 31.73% |
| 2006 | 4.09 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 13.45 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 13.45 Billion INR | -0.64% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 13.52 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 13.69 Billion INR | 0.0% |
| 2022 Q4 | 13.53 Billion INR | 0.0% |
| 2022 FY | 13.53 Billion INR | 0.14% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 13.52 Billion INR | -1.07% |
| 2021 Q4 | 13.52 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 13.52 Billion INR | 0.0% |
| 2020 Q2 | 13.32 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 13.66 Billion INR | 3.95% |
| 2020 Q4 | 13.66 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 13.14 Billion INR | 3.14% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 12.88 Billion INR | 0.0% |
| 2019 Q4 | 13.14 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 12.74 Billion INR | -1.35% |
| 2018 Q4 | 12.74 Billion INR | 0.0% |
| 2017 Q4 | 12.92 Billion INR | 0.0% |
| 2017 FY | 12.92 Billion INR | 0.94% |
| 2016 Q4 | 12.8 Billion INR | 0.0% |
| 2016 FY | 12.8 Billion INR | -1.55% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 12.98 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 13 Billion INR | 0.0% |
| 2015 Q2 | 13.05 Billion INR | 0.0% |
| 2015 FY | 13 Billion INR | 2.6% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 12.67 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 12.67 Billion INR | -1.1% |
| 2014 Q2 | 13.08 Billion INR | 0.0% |
| 2013 Q4 | 12.81 Billion INR | 0.0% |
| 2013 FY | 12.81 Billion INR | 7.68% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 12.38 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | 23.88 Billion INR | 0.0% |
| 2012 Q4 | 11.9 Billion INR | -50.17% |
| 2012 FY | 11.9 Billion INR | -4.57% |
| 2011 FY | 12.47 Billion INR | 37.44% |
| 2010 FY | 9.07 Billion INR | 21.59% |
| 2009 FY | 7.46 Billion INR | 30.4% |
| 2008 FY | 5.72 Billion INR | 6.16% |
| 2007 FY | 5.39 Billion INR | 31.73% |
| 2006 FY | 4.09 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 17.334% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 91.161% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -159.665% |
| Granules India Limited | 22.95 Billion INR | 41.393% |
| Indoco Remedies Limited | 10.34 Billion INR | -30.077% |
| Achyut Healthcare Limited | 2.01 Million INR | -668204.272% |
| Ajanta Pharma Limited | 10.71 Billion INR | -25.608% |
| Alkem Laboratories Limited | 48.6 Billion INR | 72.322% |
| Alpa Laboratories Limited | 307.12 Million INR | -4280.333% |
| Brooks Laboratories Limited | 248.6 Million INR | -5311.469% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -267.456% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -176.374% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -537.929% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 87.423% |
| Eris Lifesciences Limited | 38.26 Billion INR | 64.845% |
| FDC Limited | 3.7 Billion INR | -262.691% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 79.338% |
| Gufic Biosciences Limited | 5.59 Billion INR | -140.24% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -487.604% |
| Ipca Laboratories Limited | 33.74 Billion INR | 60.131% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -4433.281% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -352.366% |
| Lasa Supergenerics Limited | 541.92 Million INR | -2382.44% |
| Laurus Labs Limited | 42.71 Billion INR | 68.505% |
| Lupin Limited | 96.23 Billion INR | 86.021% |
| Mankind Pharma Limited | 23.87 Billion INR | 43.652% |
| Medicamen Biotech Limited | 940.36 Million INR | -1330.608% |
| Medico Remedies Limited | 438.24 Million INR | -2969.743% |
| Megasoft Limited | 1.85 Billion INR | -625.954% |
| NATCO Pharma Limited | 10.53 Billion INR | -27.734% |
| Piramal Pharma Limited | 74 Billion INR | 81.821% |
| RPG Life Sciences Limited | 1.38 Billion INR | -874.711% |
| Sigachi Industries Limited | 2.53 Billion INR | -431.472% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 92.671% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -561.33% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1054.552% |
| Unichem Laboratories Limited | 8.06 Billion INR | -66.719% |
| Wanbury Limited | 3.15 Billion INR | -326.332% |
| Windlas Biotech Limited | 1.76 Billion INR | -663.202% |
| ZIM Laboratories Limited | 2.08 Billion INR | -546.54% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 81.261% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -245.577% |
| Divi's Laboratories Limited | 18.99 Billion INR | 29.158% |
| Hester Biosciences Limited | 3.59 Billion INR | -274.242% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -425.26% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1616.325% |
| Bal Pharma Limited | 2.51 Billion INR | -435.702% |
| Strides Pharma Science Limited | 37.68 Billion INR | 64.297% |
| Venus Remedies Limited | 1.39 Billion INR | -865.894% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -63.052% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -19.922% |
| Shilpa Medicare Limited | 12.93 Billion INR | -4.025% |
| Aarti Drugs Limited | 11.5 Billion INR | -16.942% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -112.564% |
| Suven Life Sciences Limited | 148.62 Million INR | -8951.86% |
| Valiant Laboratories Limited | 1.05 Billion INR | -1171.236% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -25.635% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 4.884% |
| Themis Medicare Limited | 1.88 Billion INR | -612.736% |
| Hikal Limited | 12.99 Billion INR | -3.525% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 83.604% |
| Sequent Scientific Limited | 8.27 Billion INR | -62.588% |
| Novartis India Limited | 1.8 Billion INR | -646.93% |
| Wockhardt Limited | 39.87 Billion INR | 66.258% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 78.045% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -4558.245% |
| Neuland Laboratories Limited | 5.49 Billion INR | -144.663% |
| Morepen Laboratories Limited | 4.45 Billion INR | -201.65% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1989.349% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -580.711% |